Data / Form D filings / Starton Therapeutics Inc.
Starton Therapeutics Inc.: Form D filings
Starton Therapeutics Inc., a biotechnology company in Paramus, NJ, filed 9 Form D notices with the SEC between 2018 and 2024. The latest, on October 22, 2024, reports $2.1 million sold of a $2.1 million offering to 16 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 215 COLLEGE ROAD, SUITE #300, Paramus, NJ, 07652
- Phone
- (800) 449-5405
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- British Columbia, Canada
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1743192
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 22, 2024 | New notice | $2,126,035 | $2,126,035 | 16 | Oct 10, 2024 | sec.gov | |
| Oct 13, 2023 | New notice | $970,930 | $970,930 | 8 | Oct 1, 2023 | sec.gov | |
| Apr 13, 2023 | New notice | $1,443,520 | $1,443,520 | 7 | Mar 31, 2023 | sec.gov | |
| Jan 25, 2023 | New notice | $1,023,417 | $1,023,417 | 11 | Jan 18, 2023 | sec.gov | |
| Feb 16, 2022 | New notice | $1,145,350 | $1,145,350 | 9 | Feb 11, 2022 | sec.gov | |
| Nov 22, 2021 | New notice | $1,145,375 | $1,145,375 | 39 | Oct 19, 2021 | sec.gov | |
| May 26, 2021 | New notice | $77,597 | $77,597 | 5 | Mar 3, 2021 | sec.gov | |
| Jan 13, 2020 | New notice | Indefinite | $2,038,703 | 25 | Dec 20, 2019 | sec.gov | |
| Jul 2, 2018 | New notice | Indefinite | $766,677 | 15 | Apr 4, 2018 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Scott Kahn | Executive Officer | |
| Nitin Kaushal | Director | |
| Mohamad Hussein | Director | |
| Eric Baum | Director | |
| Roy Waldron | Director | |
| Asher Chanan-Khan | Director | |
| Pedro Lichtinger Waisman | Executive Officer, Director | |
| Kenneth Anderson | Director | |
| Moses Dodo | Director | |
| Fotios Plakogiannis | Director | |
| Jamie Oliver | Executive Officer |
Other biotechnology companies in New Jersey that filed recently
- Ensho Therapeutics, Inc. $7.3 million · Oct 15, 2026
- Xenon Ophthalmics Inc $3.3 million · Oct 6, 2026
- LISATA THERAPEUTICS, INC. $351.9 million · Oct 2, 2026
- Bullseye Biodevices, Inc. $1.3 million · Aug 10, 2026
- Hepion Pharmaceuticals, Inc. $3.1 million · Aug 5, 2026
Every Form D from the week of Oct 21, 2024 · All recent filings in New Jersey · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Starton Therapeutics Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.